All In Biotech

Free tool

FAERS Monitor: Lodoco

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215727 or its brand name (Lodoco, Colchicine). Reports on generic versions are filed under their own applications.

Reports

24

Serious

8

33% of reports

Hospitalization

2

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea4
  • abdominal discomfort3
  • pain3
  • dizziness2
  • fatigue2
  • nausea2
  • product use in unapproved indication2
  • product use issue2
  • abdominal pain1
  • abdominal pain upper1
  • adverse event1
  • back pain1
  • balance disorder1
  • chronic obstructive pulmonary disease1
  • colitis1

Reports by year received

View as table
YearReports
20071
20247
20257
20269

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,135 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
colitis123.13.45
chronic obstructive pulmonary disease116.82.53
abdominal discomfortSignal315.75.428
balance disorder110.11.52
adverse event19.51.41
product use issue29.32.58
product use in unapproved indication27.11.95
diarrhoeaSignal45.42.211
painSignal34.31.55
abdominal pain upper14.30.60
back pain13.80.60
abdominal pain13.80.60
dizziness23.50.92
fatigue22.30.60
nausea22.20.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.